Provided by Parkinson & Movement Disorder Alliance

This session will provide an in-depth overview of the gastrointestinal issues that can occur throughout the entire GI tract in Parkinson's disease. The appropriate diagnostic workup, management strategies, risk factors, and criteria for specialist referral will be covered for common GI disorders in Parkinson's.

Estimated time to complete activity: 75 minutes

Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the gastrointestinal (GI) dysfunction that can occur throughout the entire GI tract in Parkinson's disease
• Recognize the appropriate diagnostic workup and management strategies for common GI issues in Parkinson's disease
• Identify risk factors that can contribute to or exacerbate GI symptoms in Parkinson's patients
• Appraise criteria for referral to gastroenterology or other specialists for further evaluation and management of refractory or complicated GI disorders in Parkinson's disease.

Faculty

Delaram Safarpour, MD, MSCE, FAAN
Associate Professor of Neurology
Medical Director of Movement Disorders Surgical Program
Oregon Health & Science University

Dr. Safarpour earned her medical degree in Tehran, Iran in 2007, she then completed a year of post-doctoral fellowship in movement disorders at Yale University followed by residency in neurology at Temple University hospital. Being interested in the clinical and epidemiological aspects of Movement Disorders, she then earned a master's degree in neuroepidemiology and completed a fellowship in Movement Disorders at the University of Pennsylvania in Philadelphia. Her research focus has been on Gastrointestinal dysfunction in Parkinson’s disease as well effect of Deep brain stimulation in treatment of movement disorders. She has participated in many clinical trials and is the primary investigator in several ongoing PI initiated studies. Dr. Safarpour is a staff neurologist and medical director of the movement disorders surgical program at Oregon Health & Science University (OHSU). She is a member of several study groups of the International Parkinson Movement Disorders Society (MDS) and Parkinson Study Group (PSG). She has been recognized by the American academy of Neurology with A.B Baker teacher recognition award and excellence in teaching award through school of medicine at OHSU. She has authored and co-authored several peer reviewed articles and book chapters on gastrointestinal dysfunction in Parkinson’s disease as well as deep brain stimulation in treatment of movement disorders.

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Delaram Safarpour, MD, MSCE, FAAN
• Principal or site investigator for research supported by Medtronic
• Speakers’ Bureau, consultant, and/or advisory board member for Boston Scientific and AbbVie
  

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Leslie Cloud, MD
• Site investigator for research supported by Cereval Therapeutics, Bukwang Pharmaceutical, UCB Pharma, and Intracellular Therapies
• Speakers’ Bureau, consultant, and/or advisory board member for Kyowa Kirin and AbbVie
• Britt Stone, MD
• Consultant or advisory board for Boston Scientific
• Jason Rivera, MPH
• No disclosures to report
• Clarisse Goas, NP
• Principal or site investigator for research supported by Prilenia Therapeutics
• Anissa Mitchel, LCSW
• No disclosures to report
• Kelly Papesh, DNP
• Speakers’ Bureau, consultant, and/or advisory board member for Acadia, Amneal, and Supernus 

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by independent medical education grants from Acadia, Merz, AbbVie, Kyowa Kirin, and Ipsen.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org